• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

探讨吲哚胺 2,3-双加氧酶 1 在葡萄膜黑色素瘤中的表达。

Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma.

机构信息

Research Laboratory of Ophthalmology and Vision Sciences, Torsten-Wiesel Research Institute of World Eye Organization, State Key Laboratory of Biotherapy, West China Hospital, SiChuan University, Chengdu, China; Department of Ophthalmology, West China Hospital, Sichuan University, Cheng Du, Sichuan, China.

West China Hospital, Sichuan University, Cheng Du, Sichuan, China.

出版信息

Exp Eye Res. 2019 Apr;181:112-119. doi: 10.1016/j.exer.2019.01.005. Epub 2019 Jan 11.

DOI:10.1016/j.exer.2019.01.005
PMID:30639792
Abstract

The purpose of this study was to investigate indoleamine 2,3-dioxygenase 1 (IDO1) expression and its implications in uveal melanoma (UM). Bioinformatics analysis was performed on microarray data (GSE22138 and GSE27831) from the Gene Expression Omnibus (GEO) database to evaluate IDO1 expression in mRNA level. Ninety-two cases in the database were divided into the IDO1-high group (46 cases) and IDO1-low group (46 cases). Paraffin embedded tumor sections from 27 patients with UM were studied by immunofluorescence. The mRNA results showed that IDO1 expression was inversely correlated with tumor thickness (9.93 ± 3.33 mm in IDO1-high group vs. 11.56 ± 2.38 mm in IDO1-low group) (p = 0.016) and metastatic rate (30.4% in IDO1-high group vs. 69.6% in IDO1-low group, p < 0.001). The IDO1-high group showed higher immune cell gene expression: CD3D (6.56 ± 1.0 vs. 5.46 ± 0.53, p < 0.0001), CD4 (4.72 ± 0.4 vs. 4.2 ± 0.42, p < 0.0001), and CD68 (6.17 ± 1.23 vs. 5.53 ± 0.77, p = 0.015). Further analysis showed that immune-suppressive T regulatory cell genes (CD3D, CD4, IL2RA and FOXP3) were expressed in 67.4% (31/46) cases in the IDO1-high group and 23.91% (11/46) cases in the IDO1-low group. In addition, IDO1 and interferon gamma (IFNG) mRNA expression were strongly correlated (r = 0.70, p < 0.0001). The correlation analysis of different immune checkpoints showed that IDO1 was positively correlated with CD274(PDL1), but not CTLA4 or PDCD1.The disease-free survival (DFS) in the IDO1-high/IFNG-high group was better than that of the IDO1-low/IFNG-low group. The IDO1 immunostaining result showed that 2 cases in 18 UMs with Bruch's membrane (BM) rupture and 7 out of 9 cases without BM rupture were scored high (Grade 2-3) (p = 0.001). Comparing the immune cells staining results between IDO1-high group and IDO1-low group, higher percentage of patients in the former group had high levels of T cells and macrophages infiltration, but only the difference in macrophage was statistically significant (CD68, 77.78% vs. 27.78%, p = 0.04). The analysis based on GEO data and the result from immunostaining study are consistent with each other. In conclusion, the expression of IDO1 is probably induced by IFNγ from infiltrated immune cells in UM. BM rupture is an important indicator of IDO1 expression level and distribution pattern. The complex role of IDO1 may limit its therapeutic effect in UM.

摘要

本研究旨在探讨吲哚胺 2,3-双加氧酶 1(IDO1)在葡萄膜黑色素瘤(UM)中的表达及其意义。我们对来自基因表达综合数据库(GEO)的微阵列数据(GSE22138 和 GSE27831)进行了生物信息学分析,以评估 IDO1 在 mRNA 水平上的表达。数据库中的 92 例病例分为 IDO1 高表达组(46 例)和 IDO1 低表达组(46 例)。通过免疫荧光法研究了 27 例 UM 患者的石蜡包埋肿瘤切片。mRNA 结果显示,IDO1 表达与肿瘤厚度呈负相关(IDO1 高表达组为 9.93±3.33mm,IDO1 低表达组为 11.56±2.38mm)(p=0.016),与转移率呈负相关(IDO1 高表达组为 30.4%,IDO1 低表达组为 69.6%,p<0.001)。IDO1 高表达组的免疫细胞基因表达更高:CD3D(6.56±1.0 与 5.46±0.53,p<0.0001)、CD4(4.72±0.4 与 4.2±0.42,p<0.0001)和 CD68(6.17±1.23 与 5.53±0.77,p=0.015)。进一步分析显示,免疫抑制性 T 调节细胞基因(CD3D、CD4、IL2RA 和 FOXP3)在 IDO1 高表达组的 67.4%(31/46)病例和 IDO1 低表达组的 23.91%(11/46)病例中表达。此外,IDO1 和干扰素 γ(IFNG)mRNA 表达呈强相关性(r=0.70,p<0.0001)。不同免疫检查点的相关性分析显示,IDO1 与 CD274(PDL1)呈正相关,但与 CTLA4 或 PDCD1 无关。IDO1 高表达/IFNG 高表达组的无病生存率(DFS)优于 IDO1 低表达/IFNG 低表达组。IDO1 免疫染色结果显示,18 例存在布鲁赫膜(BM)破裂的 UM 中有 2 例和 9 例无 BM 破裂的 UM 中有 7 例评分较高(2-3 级)(p=0.001)。比较 IDO1 高表达组和 IDO1 低表达组的免疫细胞染色结果,前者有更高比例的患者存在 T 细胞和巨噬细胞浸润,但是只有巨噬细胞的差异有统计学意义(CD68,77.78%与 27.78%,p=0.04)。基于 GEO 数据的分析和免疫组化研究的结果是一致的。总之,IDO1 的表达可能是由浸润的免疫细胞中的 IFNγ 诱导的。BM 破裂是 IDO1 表达水平和分布模式的一个重要指标。IDO1 的复杂作用可能限制了其在 UM 中的治疗效果。

相似文献

1
Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma.探讨吲哚胺 2,3-双加氧酶 1 在葡萄膜黑色素瘤中的表达。
Exp Eye Res. 2019 Apr;181:112-119. doi: 10.1016/j.exer.2019.01.005. Epub 2019 Jan 11.
2
Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.吲哚胺 2,3-双加氧酶 1(IDO1)表达和催化活性的上调与阴茎鳞癌患者的免疫抑制和预后不良有关。
Cancer Commun (Lond). 2020 Jan;40(1):3-15. doi: 10.1002/cac2.12001. Epub 2020 Mar 3.
3
Implications of LAG3 and CTLA4 immune checkpoints beyond PD-1/PD-L1 as a potential target in determining the prognosis of uveal melanoma patients.LAG3 和 CTLA4 免疫检查点除 PD-1/PD-L1 以外作为预测葡萄膜黑色素瘤患者预后的潜在靶点的意义。
Br J Ophthalmol. 2024 May 21;108(6):903-912. doi: 10.1136/bjo-2022-322913.
4
Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma.免疫检查点受体吲哚胺 2,3-双加氧酶和 T 细胞免疫球蛋白和 ITIM 结构域在转移性与非转移性脉络膜黑色素瘤中的表达。
Cancer Med. 2019 Jun;8(6):2784-2792. doi: 10.1002/cam4.2167. Epub 2019 Apr 16.
5
Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.鉴定选择性色氨酸 2,3-双加氧酶-1(IDO1)催化抑制剂 EOS200271/PF-06840003 支持 IDO1 作为 PD-(L)1 阻断疗法耐药的关键机制。
Mol Cancer Ther. 2018 Dec;17(12):2530-2542. doi: 10.1158/1535-7163.MCT-17-1104. Epub 2018 Sep 19.
6
CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer.肿瘤浸润免疫细胞中 CD274、LAG3 和 IDO1 的表达作为 MSI-高结直肠癌患者的预后生物标志物。
J Cancer Res Clin Oncol. 2018 Jun;144(6):1005-1014. doi: 10.1007/s00432-018-2620-x. Epub 2018 Mar 8.
7
IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer.IDO1 表达与手术切除的食管癌患者的免疫耐受和不良预后相关。
Ann Surg. 2019 Jun;269(6):1101-1108. doi: 10.1097/SLA.0000000000002754.
8
Expression of nm23-H1 in uveal melanoma.nm23-H1在葡萄膜黑色素瘤中的表达。
Melanoma Res. 2007 Oct;17(5):284-90. doi: 10.1097/CMR.0b013e3282eeea5a.
9
Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma.肝癌中吲哚胺 2,3-双加氧酶 1 的表达机制及其预后价值。
Cancer Sci. 2018 Dec;109(12):3726-3736. doi: 10.1111/cas.13811. Epub 2018 Nov 5.
10
Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.吲哚胺 2,3-双加氧酶 1 和程序性死亡配体 1 的共表达与肺腺癌的侵袭性特征相关。
Eur J Cancer. 2018 Sep;101:20-29. doi: 10.1016/j.ejca.2018.06.020. Epub 2018 Jul 13.

引用本文的文献

1
Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors.γ干扰素在黑色素瘤患者对免疫检查点抑制剂免疫治疗反应中的双重作用
Mol Cancer. 2025 Mar 20;24(1):89. doi: 10.1186/s12943-025-02294-x.
2
Radiotherapy-Related Gene Signature in Prostate Cancer.前列腺癌中与放疗相关的基因特征
Cancers (Basel). 2022 Oct 14;14(20):5032. doi: 10.3390/cancers14205032.
3
A Comprehensive Prognostic and Immunological Analysis of a Six-Gene Signature Associated With Glycolysis and Immune Response in Uveal Melanoma.
全面的预后和免疫分析与葡萄膜黑色素瘤中糖酵解和免疫反应相关的六个基因特征。
Front Immunol. 2021 Sep 22;12:738068. doi: 10.3389/fimmu.2021.738068. eCollection 2021.
4
Bioinformatic Analysis Reveals Central Role for Tumor-Infiltrating Immune Cells in Uveal Melanoma Progression.生物信息学分析揭示肿瘤浸润免疫细胞在葡萄膜黑色素瘤进展中的核心作用。
J Immunol Res. 2021 Jun 11;2021:9920234. doi: 10.1155/2021/9920234. eCollection 2021.
5
Identification of an immune-related signature for the prognosis of uveal melanoma.葡萄膜黑色素瘤预后的免疫相关特征识别。
Int J Ophthalmol. 2020 Mar 18;13(3):458-465. doi: 10.18240/ijo.2020.03.14. eCollection 2020.